Paget's and the Rheumatologist: Why Haven't I Seen This Yet?
Click Here to Manage Email Alerts
What is Paget’s? Why is it declining across much of the globe? Find out, plus hear an interview with the head of the center for osteoporosis and metabolic bone disease at Cleveland Clinic, Chad Deal, MD.
Brought to you by GSK.
- Intro :11
- Today’s episode :27
- What is Paget’s? 1:07
- The history of Paget’s 5:35
- How often is this symptomatic? 9:30
- The epidemiology of Paget’s 13:22
- The data on viruses and Paget’s disease 21:08
- An interview with Dr. Chad Deal25:09
- The numbers are showing a decline in Paget’s disease, are you seeing that? 26:03
- Identifying Paget’s disease … who’s picking this up? 27:01
- Can you walk us through those studies again? 27:58
- Can you tell us a little bit about hypervascularity found in these patients? 30:32
- Can you walk us through the history of how the treatments have changed? 31:37
- Paget’s kind of just doesn’t go anywhere … is that what you’ve seen in your practice? 35:05
- What if the patient has poor or borderline kidney function? Do they have other options? 37:07
- Have you seen familial cases? Are people more prone to get it if someone in the family has it? 38:32
- A discussion on osteosarcoma 39:55
- Dr. Deal, thank you so much for your time and your knowledge about metabolic bone 42:46
- Episode summary 42:52
- I hope you learned something and thanks for listening! 44:47
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Cundy T. Metabolism. 2018;80:5-14.
Haddaway MJ, et al. Br J Radiol. 2007;80:523-526.
Poór G, et al. J Bone Miner Res. 2006;21:1545-1549.
Renier JC, Audran M. Rev Rhum Engl Ed. 1997;64:35-43.
Shaw B, et al. Proc Natl Acad Sci USA. 2019;10463-10472.
Singer FR. Nat Rev Endocrinol. 2015;11:662-671.
Wermers RA, et al. J Bone Miner Res. 2008;23:819-825.
Collapse
Read more about
Click Here to Manage Email Alerts
